Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chimerix, Inc. stock logo
CMRX
Chimerix
$8.54
$8.54
$0.75
$8.55
$801.09M-0.172.81 million shsN/A
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
$19.00
$18.88
$8.82
$21.86
$794.77M0.881.36 million shsN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$0.23
$0.06
$1.35
$1.87M2.183.66 million shs29.90 million shs
Veru Inc. stock logo
VERU
Veru
$0.60
+2.2%
$0.57
$0.45
$1.42
$87.51M-0.751.93 million shs784,557 shs
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
$1.08
$0.77
$5.95
$187.12M1.712.01 million shs2.13 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chimerix, Inc. stock logo
CMRX
Chimerix
0.00%0.00%0.00%+0.23%+918.36%
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
0.00%0.00%0.00%0.00%-91.32%
Veru Inc. stock logo
VERU
Veru
+5.37%-2.80%-12.79%+7.46%-33.80%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Chimerix, Inc. stock logo
CMRX
Chimerix
0.6709 of 5 stars
1.00.00.04.10.01.70.6
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/AN/AN/AN/AN/A
Veru Inc. stock logo
VERU
Veru
1.9288 of 5 stars
3.53.00.00.00.61.70.0
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chimerix, Inc. stock logo
CMRX
Chimerix
2.00
Hold$8.53-0.08% Downside
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
0.00
N/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
0.00
N/AN/AN/A
Veru Inc. stock logo
VERU
Veru
3.00
Buy$4.00571.14% Upside
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chimerix, Inc. stock logo
CMRX
Chimerix
$212K3,778.71N/AN/A$2.17 per share3.94
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
$285.71M2.78N/AN/A$1.72 per share11.05
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$9.41M0.00N/AN/A$0.32 per share0.00
Veru Inc. stock logo
VERU
Veru
$16.89M5.17N/AN/A$0.22 per share2.71
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A$0.58 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chimerix, Inc. stock logo
CMRX
Chimerix
-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%8/11/2025 (Estimated)
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
$221.82M-$1.48N/A9.84N/A-19.39%-77.48%-11.99%N/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
-$92.84MN/A0.00N/AN/A-881.79%-525.42%-45.87%N/A
Veru Inc. stock logo
VERU
Veru
-$37.80M-$0.24N/AN/AN/AN/A-128.51%-76.51%8/6/2025 (Estimated)
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/A

Latest ICPT, CMRX, ZIOP, VBIV, and VERU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q2 2025
Veru Inc. stock logo
VERU
Veru
-$0.06-$0.05+$0.01-$0.05$0.73 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Chimerix, Inc. stock logo
CMRX
Chimerix
N/AN/AN/AN/AN/A
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
N/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/AN/A
Veru Inc. stock logo
VERU
Veru
N/AN/AN/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chimerix, Inc. stock logo
CMRX
Chimerix
N/A
6.33
6.33
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
3.12
4.22
2.52
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/A
0.34
0.21
Veru Inc. stock logo
VERU
Veru
N/A
3.80
3.80
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.18
3.43
3.43

Institutional Ownership

CompanyInstitutional Ownership
Chimerix, Inc. stock logo
CMRX
Chimerix
45.42%
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
83.81%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
12.26%
Veru Inc. stock logo
VERU
Veru
47.16%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
51.03%

Insider Ownership

CompanyInsider Ownership
Chimerix, Inc. stock logo
CMRX
Chimerix
13.10%
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
6.20%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
10.35%
Veru Inc. stock logo
VERU
Veru
15.20%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
5.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Chimerix, Inc. stock logo
CMRX
Chimerix
9093.80 million78.15 millionOptionable
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
34141.83 million39.19 millionOptionable
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
2228.68 million25.71 millionOptionable
Veru Inc. stock logo
VERU
Veru
230146.58 million124.30 millionOptionable
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
105216.15 million204.91 millionOptionable

Recent News About These Companies

Best Global Universities for Oncology
FDA fast-tracks Merck's cancer blockbuster-in-waiting
Childhood Cancers
Alx Oncology Holdings (ALXO)
Pediatric Hematology-Oncology Fellowship
CG Oncology Inc
Immuno-Oncology
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
Association of Community Cancer Centers
Oncology News and Research
WBSPH 2024 - Oncology
Kris on Oncology
Oncology Cases & Quizzes

New MarketBeat Followers Over Time

Media Sentiment Over Time

Chimerix stock logo

Chimerix NASDAQ:CMRX

$8.54 0.00 (0.00%)
As of 04/21/2025

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Intercept Pharmaceuticals stock logo

Intercept Pharmaceuticals NASDAQ:ICPT

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..

VBI Vaccines stock logo

VBI Vaccines NASDAQ:VBIV

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

Veru stock logo

Veru NASDAQ:VERU

$0.60 +0.01 (+2.19%)
As of 10:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

ZIOPHARM Oncology stock logo

ZIOPHARM Oncology NASDAQ:ZIOP

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.